HLA-A*02:01 Allele Frequency and the NY-ESO-1 Expression Status in Cancer Patients in Taiwan

Clinical trial NCT06665776 · TERMINATED

Trial details

NCT number: NCT06665776
Sponsor: PharmaEssentia
Status: TERMINATED
Study type: OBSERVATIONAL

Solid Tumor Malignancy

Start date: 2023-03-14
Primary completion: 2026-05-27
Enrollment: 485

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.